

MANGROVE INSURANCE EUROPE PCC LTD



A cell in a PCC captive may be the ideal solution for organizations looking to retain risk and who have a business need to segregate insurance assets and liabilities. This segregation may be required for numerous reasons, including the need to separate assets and liabilities by division or territory; by risks associated with a joint venture, by a special project or a strategic alliance; or by risks associated with companies' regulated and non-regulated businesses. Additionally, a cell can provide clients with access to the reinsurance market by participating as a fronting vehicle to access reinsurers, or as a risk retention vehicle by assuming risk from the commercial marketplace.

Marsh Captive Solutions has formed Mangrove PCC facilities in Malta, the Isle of Man, and Washington, DC to take advantage of the PCC legislation in these domiciles. The Mangrove PCC facilities, each ultimately owned by Marsh LLC ("Sponsor") and managed by Marsh Captive Solutions ("Manager"), can provide clients with a cost effective risk financing vehicle in which assets and liabilities are segregated.

SERVICE HIGHLIGHTS

What is a PCC?

A Protected Cell Company ("PCC") is a company structured in accordance with applicable PCC legislation. The PCC structure creates a legal segregation of its assets and liabilities into a number of different cells and a central core. The purpose of such an arrangement is to effectively 'ring-fence' the assets and liabilities of each cell and offer protection to cell owners from the liabilities and creditors of other cells. Although each cell's assets and liabilities are segregated from those of the core and of all other cells, the PCC is a single legal entity.

Who it's for

- Companies too small, based upon premium spend, to form a single parent captive.
- Companies that want a low-cost alternative with low-touch administrative effort instead of a wholly owned captive insurance company or wish to save time on Solvency II implementation.
- Companies who wish to increase their capital efficiency.
- Companies who put their existing captive into run-off could transfer risk into a cell, enabling the release of capital and responsibility from their stand-alone captive.
- Companies with high levels of predictable losses.
- Companies that seek to direct write/front in the EU or non-EU/European Economic Area (EEA) captives.
- Companies with a need to segregate risks associated with specific project, division, joint-venture or strategic alliance.

What you get

The owner of a cell in Mangrove may receive some or all of the following benefits:

- Cost effective risk-financing vehicle.
- Reduced overall insurance spend.
- Access to the reinsurance market.
- Cover for uninsurable or "difficult to place" risks.
- Flexibility in programme design.
- Minimal management time requirement.
- Optimization of risk transfer and risk retention.
- Ability to provide governance and compliance reporting for Solvency II.
- Statutory segregation of various risks.
- Ability to access Insurance Linked Securities (ILS) or Reinsurance Special Purpose Vehicles (RSVPs).


Mangrove is a PCC that is licensed under applicable insurance laws and regulations to write insurance and reinsurance risks. Mangrove was set up with the purpose of offering cells that would insure and/or reinsure the risks of each cell shareholder. The cell shareholder is unrelated to the sponsor and to other cell shareholders.

THE VALUE OF A MALTA PCC

Malta has an excellent international business reputation and a stable, independent government. Malta has a triple-A sovereign rating, quality infrastructure and the capacity to grow. A PCC domiciled in Malta benefits from a robust PCC and captive legislation. Malta captive regulation has highly competitive capital and solvency requirements and a captive or cell typically enjoys the unlimited ability to mix the amount of non life insurance and reinsurance business that can be written. The time required to start a cell in Malta is approximately three months.

MANGROVE PCC STRUCTURE IN MALTA

Mangrove requires that cell owners enter into Participation, Subscription, and Management Agreements with the Sponsor. Non-voting shares are issued to each cell owner, who pay their share of the ongoing costs through a flat fee for administration.



As a general matter, a legal separation exists between each of the cells within the PCC. This protects the owners of one cell from any losses attributable to other cells within the PCC, subject to the satisfaction of all required conditions.

The Manager will develop a business plan on behalf of the cell owner and submit the plan to the Sponsor for approval. The business plan and the licence application will then be sent to the insurance regulator for review and approval. The Manager will work with the cell owner to determine the amount of capital needed for the owner’s individual cell to satisfy the capital funding requirements set by the Sponsor and the regulator. Capital may be contributed in the form of cash or an approved letter of credit. Under certain circumstances, additional forms of capital may be contributed with approval of the insurance regulator and the Sponsor.

ABOUT MARSH CAPTIVE SOLUTIONS

Marsh Captive Solutions, comprised of more than 400 captive advisory and management experts located throughout the globe, provides specialized expertise and strategic resources to help create a comprehensive, results-focused captive solution to meet a client’s risk management needs. Marsh has been an integral part of the captive industry for 50 years, currently managing more than 1,250 single-parent captives, in addition to reinsurance pools, risk retention groups, and other captive solutions.

For further information, please contact your local Marsh office or visit our web site at: marshcaptivesolutions.com

DAVID GALEA
Mangrove Insurance Europe PCC Ltd
david.galea@marsh.com

STEPHEN PORTELLI
Mangrove Insurance Europe PCC Ltd
stephen.portelli@marsh.com

Marsh is one of the Marsh & McLennan Companies, together with Guy Carpenter, Mercer, and Oliver Wyman.

This document is not intended to be taken as advice regarding any individual situation and should not be relied upon as such. The information contained herein is based on sources we believe reliable, but we make no representation or warranty as to its accuracy. Marsh shall have no obligation to update this publication and shall have no liability to you or any other party arising out of this publication or any matter contained herein.

Any statements concerning actuarial, tax, accounting, or legal matters are based solely on our experience as insurance brokers and risk consultants and are not to be relied upon as actuarial, accounting, tax, or legal advice, for which you should consult your own professional advisors.

Any modeling, analytics, or projections are subject to inherent uncertainty, and the Marsh Analysis could be materially affected if any underlying assumptions, conditions, information, or factors are inaccurate or incomplete or should change.

Marsh makes no representation or warranty concerning the application of policy wordings or the financial condition or solvency of insurers or re-insurers. Marsh makes no assurances regarding the availability, cost, or terms of insurance coverage.